Topiramate (Qudexy XR) vs Topiramate (Topamax Sprinkle)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline

Topiramate (Qudexy XR)

Marketed by Upsher-Smith Laboratories, LLC

Approved in Epilepsysmall molecule
Reliable signal

NCT01142193 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 249 participants. The primary clinical endpoint—percent reduction in weekly partial-onset seizure frequency over 11 weeks—was met, with a statistically significant advantage for USL255 over placebo (p<0.001).

Reported efficacy

Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) (met)

Result source: NCT01142193

Topiramate (Topamax Sprinkle)

Marketed by Johnson & Johnson

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTopiramate (Qudexy XR)Topiramate (Topamax Sprinkle)
Seizure frequency, % change—Not posted · NCT00236717—Not reported
50% responder rate33.9% vs 17.6%+16.3 vs placebowk 3 · n 124NCT01142193—Not reported
Seizure freedom—Not posted · NCT00236717—Not reported

Seizure frequency, % change

Topiramate (Qudexy XR)
—Not posted · NCT00236717
Topiramate (Topamax Sprinkle)
—Not reported

50% responder rate

Topiramate (Qudexy XR)
33.9% vs 17.6%+16.3 vs placebowk 3 · n 124NCT01142193
Topiramate (Topamax Sprinkle)
—Not reported

Seizure freedom

Topiramate (Qudexy XR)
—Not posted · NCT00236717
Topiramate (Topamax Sprinkle)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Topiramate (Topamax Sprinkle): no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Topiramate (Qudexy XR): 4 of 4 rows · Topiramate (Topamax Sprinkle): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTopiramate (Qudexy XR)
Dropout rate
16.9%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Discontinued due to AEs
9.7%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Serious AEs
1.6%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Most frequent reported AEs
somnolence 12.1% (placebo 2.4%)
dizziness 7.3% (placebo 5.6%)
paraesthesia 6.5% (placebo 2.4%)
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Topiramate (Qudexy XR)

Seizure 50 37.9% (n=124) vs 23.2% (n=125) placebo @ 11wk
responder rate · % of participants
Maintenance
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 1 more result
44.2% (n=113) vs 30.8% (n=120) placebo @ 8wk
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Seizure 50 33.9% (n=124) vs 17.6% (n=125) placebo @ 3wk
responder rate · % of participants
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Qudexy XR)'s landscape · Topiramate (Topamax Sprinkle)'s landscape